Table 2.
Association of Inflammatory Markers with Incident Inability to Complete the 400 m Walk at Follow-Up
| Models Ia
|
Models IIb
|
Models IIIc
|
Models IVd
|
|||||
|---|---|---|---|---|---|---|---|---|
| OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | |
| IL-6 (pg/mL) | ||||||||
| Q1 (≤ 2.034724) | Reference | Reference | Reference | Reference | ||||
| Q2 (>2.034724, ≤ 2.978014) | 1.2 | (0.7–2.1) | 1.1 | (0.6–1.9) | 1.0 | (0.6–1.8) | 0.9 | (0.5–1.7) |
| Q3 (>2.978014, ≤ 4.133125) | 1.4 | (0.8–2.4) | 1.2 | (0.7–2.1) | 1.1 | (0.6–1.9) | 1.0 | (0.5–1.8) |
| Q4 (>4.133125) | 2.4 | (1.4–4.3) | 1.8 | (1.0–3.3) | 1.4 | (0.8–2.7) | 1.3 | (0.7–2.7) |
| p for trend | p < .01 | p = 0.06 | p = 0.29 | p = 0.43 | ||||
| IL-6R (pg/mL) | ||||||||
| Q1 (≤ 69.152) | Reference | Reference | Reference | Reference | ||||
| Q2 (>69.152, ≤ 93.379) | 1.3 | (0.7–2.2) | 1.2 | (0.7–2.3) | 1.7 | (0.9–3.0) | 2.1 | (1.1–4.0) |
| Q3 (>93.379, ≤ 125.723) | 1.6 | (0.9–2.7) | 1.4 | (0.8–2.5) | 1.6 | (0.8–2.9) | 1.9 | (1.0–3.8) |
| Q4 (>125.723) | 0.8 | (0.4–1.4) | 0.8 | (0.4–1.5) | 1.0 | (0.5–1.8) | 1.1 | (0.5–2.2) |
| p for trend | p = 0.60 | p = 0.62 | p = 0.93 | p = 0.80 | ||||
| CRP (mg/L) | ||||||||
| Q1 (≤ 1.320) | Reference | Reference | Reference | Reference | ||||
| Q2 (>1.320, ≤ 2.765) | 1.0 | (0.6–1.8) | 0.9 | (0.5–1.7) | 0.8 | (0.5–1.5) | 0.8 | (0.4–1.4) |
| Q3 (>2.765, ≤ 5.800) | 1.2 | (0.7–2.1) | 1.3 | (0.7–2.2) | 1.0 | (0.6–1.7) | 1.0 | (0.5–1.7) |
| Q4 (>5.800) | 1.4 | (0.8–2.5) | 1.3 | (0.7–2.4) | 1.0 | (0.5–1.9) | 0.9 | (0.4–1.8) |
| p for trend | p = 0.18 | p = 0.29 | p = 0.94 | p = 0.82 | ||||
| TNF-α (pg/mL) | ||||||||
| Q1 (≤ 3.29) | Reference | Reference | Reference | Reference | ||||
| Q2 (>3.29, ≤ 4.62) | 1.1 | (0.6–1.9) | 0.8 | (0.5–1.5) | 0.7 | (0.4–1.3) | 0.7 | (0.4–1.4) |
| Q3 (>4.62, ≤ 6.07) | 1.4 | (0.9–2.5) | 1.2 | (0.7–2.2) | 1 | (0.6–1.9) | 1.0 | (0.5–1.8) |
| Q4 (>6.07) | 1.4 | (0.8–2.5) | 1.0 | (0.5–1.5) | 0.8 | (0.4–1.6) | 0.8 | (0.4–1.5) |
| p for trend | p = 0.14 | p = 0.67 | p = 0.89 | p = 0.67 | ||||
| TNFR1 (pg/mL) | ||||||||
| Q1 (≤ 1100.00) | Reference | Reference | Reference | Reference | ||||
| Q2 (>1100.00, ≤ 1351.05) | 2.7 | (1.4–4.9) | 2.6 | (1.4–4.8) | 2.6 | (1.4–5.1) | 3.1 | (1.5–6.4) |
| Q3 (>1351.05, ≤ 1724.60) | 3.0 | (1.6–5.6) | 2.2 | (1.1–4.3) | 2.0 | (1.0–4.0) | 2.4 | (1.1–5.1) |
| Q4 (>1724.60) | 5.1 | (2.7–9.9) | 3.1 | (1.6–6.2) | 2.4 | (1.1–5.1) | 2.8 | (1.2–6.5) |
| p for trend | p < .01 | p < .01 | p = 0.05 | p = 0.03 | ||||
| TNFR2 (pg/mL) | ||||||||
| Q1 (≤ 2287.0) | Reference | Reference | Reference | Reference | ||||
| Q2 (>2287.0, ≤ 2651.8) | 1.4 | (0.8–2.4) | 1.2 | (0.7–2.0) | 1 | (0.6–1.9) | 1.3 | (0.7–2.4) |
| Q3 (>2651.8, ≤ 3177.5) | 1.8 | (1.0–3.2) | 1.4 | (0.8–2.6) | 1.4 | (0.7–2.5) | 1.4 | (0.7–2.8) |
| Q4 (>3177.5) | 3.7 | (2.1–6.5) | 1.9 | (1.0–3.6) | 1.5 | (0.7–3.1) | 1.5 | (0.7–3.3) |
| p for trend | p < .01 | p = 0.05 | p = 0.19 | p = 0.26 | ||||
| IL-1RA (pg/mL) | ||||||||
| Q1 (≤ 96.590) | Reference | Reference | Reference | Reference | ||||
| Q2 (>96.590, ≤ 132.865) | 1.1 | (0.7–1.9) | 1.0 | (0.6–1.7) | 0.9 | (0.5–1.5) | 0.9 | (0.5–1.5) |
| Q3 (>132.865, ≤ 185.875) | 1.0 | (0.6–1.7) | 1.0 | (0.5–1.7) | 0.8 | (0.4–1.5) | 0.7 | (0.3–1.3) |
| Q4 (>185.875) | 1.1 | (0.6–1.9) | 1.1 | (0.6–2.0) | 0.9 | (0.5–1.5) | 0.8 | (0.4–1.5) |
| p for trend | p = 0.91 | p = 0.76 | p = 0.54 | p = 0.28 | ||||
| IL-18 (μg/mL) | ||||||||
| Q1 (≤ 302.39) | Reference | Reference | Reference | Reference | ||||
| Q2 (>302.39, ≤ 383.30) | 0.9 | (0.6–1.6) | 1.3 | (0.7–2.2) | 1.1 | (0.6–2.0) | 1.2 | (0.6–2.3) |
| Q3 (>383.30, ≤ 482.96) | 0.8 | (0.5–1.4) | 0.8 | (0.4–1.5) | 0.7 | (0.4–1.3) | 0.7 | (0.4–1.4) |
| Q4 (>482.96) | 1.5 | (0.9–2.5) | 2.0 | (1.1–3.7) | 1.5 | (0.8–2.9) | 1.3 | (0.6–2.7) |
| p for trend | p = 0.30 | p = 0.14 | p = 0.57 | p = 0.96 | ||||
OR = Odds Ratio; CI = Confidence Interval
Models I = Unadjusted bivariate models
Models II = Age and sex adjusted models
Models III = Adjusted for Model II covariates as well as body mass index, education, total number of medical conditions (includes arthritis, cancer, coronary heart disease, chronic obstructive pulmonary disease, diabetes, hip fracture, peripheral arterial disease, stroke)
Models IV = Adjusted for Model III and the following physiologic measures: MMSE, nerve conduction velocity, leg muscle power, serum hemoglobin, ankle-brachial index
Models I–III are based on an analysis sample of 1006 observations representing 621 respondents
Models IV are based on an analysis sample of 941 observations representing 621 respondents
p< 0.05 (bolded)